![logo](/logos/LPTX.webp)
Leap Therapeutics, Inc.
NASDAQ:LPTX
2.81 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Leap Therapeutics, Inc. |
Symbool | LPTX |
Munteenheid | USD |
Prijs | 2.81 |
Beurswaarde | 107,523,245 |
Dividendpercentage | 0% |
52-weken bereik | 1.235 - 5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Douglas E. Onsi J.D. |
Website | https://www.leaptx.com |
An error occurred while fetching data.
Over Leap Therapeutics, Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)